HomeCompareVGCIX vs MRK

VGCIX vs MRK: Dividend Comparison 2026

VGCIX yields 4.84% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $29.3K in total portfolio value
10 years
VGCIX
VGCIX
● Live price
4.84%
Share price
$9.61
Annual div
$0.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.5K
Annual income
$659.89
Full VGCIX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VGCIX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVGCIXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VGCIX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VGCIX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VGCIX
Annual income on $10K today (after 15% tax)
$411.47/yr
After 10yr DRIP, annual income (after tax)
$560.91/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $7,767.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VGCIX + MRK for your $10,000?

VGCIX: 50%MRK: 50%
100% MRK50/50100% VGCIX
Portfolio after 10yr
$42.1K
Annual income
$5,229.02/yr
Blended yield
12.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VGCIX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VGCIX buys
0
MRK buys
0
No recent congressional trades found for VGCIX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVGCIXMRK
Forward yield4.84%2.76%
Annual dividend / share$0.47$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$27.5K$56.8K
Annual income after 10y$659.89$9,798.13
Total dividends collected$5.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VGCIX vs MRK ($10,000, DRIP)

YearVGCIX PortfolioVGCIX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,184$484.08$11,206$366.19$22.00MRK
2$12,473$505.98$12,650$502.35$177.00MRK
3$13,873$527.37$14,407$694.19$534.00MRK
4$15,393$548.21$16,585$967.82$1.2KMRK
5$17,039$568.46$19,342$1,363.89$2.3KMRK
6$18,820$588.08$22,913$1,947.19$4.1KMRK
7$20,744$607.05$27,662$2,823.89$6.9KMRK
8$22,821$625.35$34,159$4,173.35$11.3KMRK
9$25,062$642.97$43,337$6,308.80$18.3KMRK
10$27,476$659.89$56,776$9,798.13$29.3KMRK

VGCIX vs MRK: Complete Analysis 2026

VGCIXStock

This fund seeks to provide a moderate and sustainable level of current income by investing in a diversified portfolio of global credit bonds. The fund is actively managed and invests primarily in investment-grade corporate and non-corporate obligations, excluding government-guaranteed issues. The portfolio invests in U.S. and non-U.S. securities including developed and emerging markets. The majority of non-U.S. exposure will be hedged to the U.S. dollar. This hedging enables investors to pursue a globally-diversified credit premium without adding currency risk. Like other bond funds, the fund is subject to interest rate risk; increases in interest rates may lead the price of the bonds in the portfolio to decrease, reducing the fund’s NAV. The fund is also subject to emerging markets risk—bonds in these countries tend to be more volatile and less liquid than those in developed countries—and other international risks, such as country/regional risk. Long-term, risk-tolerant investors who want to diversify their bond portfolio may wish to consider this fund.

Full VGCIX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VGCIX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VGCIX vs SCHDVGCIX vs JEPIVGCIX vs OVGCIX vs KOVGCIX vs MAINVGCIX vs JNJVGCIX vs ABBVVGCIX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.